Somatic acquisition and signaling of TGFBR1*6A in cancer

Boris Pasche, Thomas J. Knobloch, Yansong Bian, Junjian Liu, Sharbani Phukan, Diana Rosman, Virginia Kaklamani, Lisa Baddi, Farida S. Siddiqui, Wendy Frankel, Thomas W. Prior, David E. Schuller, Amit Agrawal, Jas Lang, M. Eileen Dolan, Everett E. Vokes, William S. Lane, Chiang Ching Huang, Trinidad Caldes, Antonio Di CristofanoHeather Hampel, IngMarie Nilsson, Gunnar Von Heijne, Riccardo Fodde, V. V V S Murty, Albert De La Chapelle, Christopher M. Weghorst

Research output: Contribution to journalArticle

68 Citations (Scopus)

Abstract

Context: TGFBR1*6A is a common polymorphis of the type I transforming growth factor β receptor (TGFBR1). Epidemiological studies suggest that TGFBR1*6A may act as a tumor susceptibility allele. How TGFBR1*6A contributes to cancer development is largely unknown. Objectives: To determine whether TGFBR1*6A is somatically acquired by primary tumors and metastases during cancer development and whether the 3-amino acid deletion that differentiates TGFBR1*6A from TGFBR1 is part of the mature receptor or part of the signal sequence and to investigate TGFBR1*6A signaling in cancer cells. Design, Setting, and Patients: Tumor and germline tissues from 531 patients with a diagnosis of head and neck, colorectal, or breast cancer recruited from 3 centers in the United States and from 1 center in Spain from June 1, 1994, through June 30, 2004. In vitro translation assays, MCF-7 breast cancer cells stably transfected with TGFBR1*6A, TGFBR1, or the vector alone, DLD-1 colorectal cancer cells that endogenously carry TGFBR1*6A, and SW48 colorectal cancer cells that do not carry TGFBR1*6A. Main Outcome Measures: TGFBR1*6A somatic acquisition in cancer. Determination of the amino terminus of the mature TGFBR1*6A and TGFBR1 receptors. Determination of TGF-β-dependent cell proliferation. Results: TGFBR1*6A was somatically acquired in 13 of 44 (29.5%) colorectal cancer metastases, in 4 of 157 (2.5%) of colorectal tumors, in 4 of 226 (1.8%) head and neck primary tumors, and in none of the 104 patients with breast cancer. TGFBR1*6A somatic acquisition is not associated with loss of heterozygosity, microsatellite instability, or a mutator phenotype. The signal sequences of TGFBR1 and TGFBR1*6A are cleaved at the same site resulting in identical mature receptors. TGFBR1*6A may switch TGF-β growth inhibitory signals into growth stimulatory signals in MCF-7 breast cancer cells and in DLD-1 colorectal cancer cells. Conclusions: TGFBR1*6A is somatically acquired in 29.5% of liver metastases from colorectal cancer and may bestow cancer cells with a growth advantage in the presence of TGF-β. The functional consequences of this conversion appear to be mediated by the TGFBR1*6A signal sequence rather than by the mature receptor. The results highlight a new facet of TGF-β signaling in cancer and suggest that TGFBR1*6A may represent a potential therapeutic target in cancer.

Original languageEnglish (US)
Pages (from-to)1634-1646
Number of pages13
JournalJournal of the American Medical Association
Volume294
Issue number13
DOIs
StatePublished - Oct 5 2005
Externally publishedYes

Fingerprint

Colorectal Neoplasms
Neoplasms
Protein Sorting Signals
Breast Neoplasms
Neoplasm Metastasis
Growth
Microsatellite Instability
Growth Factor Receptors
Loss of Heterozygosity
Transforming Growth Factors
Head and Neck Neoplasms
Spain
Epidemiologic Studies
Neck
Alleles
Head
Cell Proliferation
Outcome Assessment (Health Care)
Phenotype
Amino Acids

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Pasche, B., Knobloch, T. J., Bian, Y., Liu, J., Phukan, S., Rosman, D., ... Weghorst, C. M. (2005). Somatic acquisition and signaling of TGFBR1*6A in cancer. Journal of the American Medical Association, 294(13), 1634-1646. https://doi.org/10.1001/jama.294.13.1634

Somatic acquisition and signaling of TGFBR1*6A in cancer. / Pasche, Boris; Knobloch, Thomas J.; Bian, Yansong; Liu, Junjian; Phukan, Sharbani; Rosman, Diana; Kaklamani, Virginia; Baddi, Lisa; Siddiqui, Farida S.; Frankel, Wendy; Prior, Thomas W.; Schuller, David E.; Agrawal, Amit; Lang, Jas; Dolan, M. Eileen; Vokes, Everett E.; Lane, William S.; Huang, Chiang Ching; Caldes, Trinidad; Di Cristofano, Antonio; Hampel, Heather; Nilsson, IngMarie; Von Heijne, Gunnar; Fodde, Riccardo; Murty, V. V V S; De La Chapelle, Albert; Weghorst, Christopher M.

In: Journal of the American Medical Association, Vol. 294, No. 13, 05.10.2005, p. 1634-1646.

Research output: Contribution to journalArticle

Pasche, B, Knobloch, TJ, Bian, Y, Liu, J, Phukan, S, Rosman, D, Kaklamani, V, Baddi, L, Siddiqui, FS, Frankel, W, Prior, TW, Schuller, DE, Agrawal, A, Lang, J, Dolan, ME, Vokes, EE, Lane, WS, Huang, CC, Caldes, T, Di Cristofano, A, Hampel, H, Nilsson, I, Von Heijne, G, Fodde, R, Murty, VVVS, De La Chapelle, A & Weghorst, CM 2005, 'Somatic acquisition and signaling of TGFBR1*6A in cancer', Journal of the American Medical Association, vol. 294, no. 13, pp. 1634-1646. https://doi.org/10.1001/jama.294.13.1634
Pasche B, Knobloch TJ, Bian Y, Liu J, Phukan S, Rosman D et al. Somatic acquisition and signaling of TGFBR1*6A in cancer. Journal of the American Medical Association. 2005 Oct 5;294(13):1634-1646. https://doi.org/10.1001/jama.294.13.1634
Pasche, Boris ; Knobloch, Thomas J. ; Bian, Yansong ; Liu, Junjian ; Phukan, Sharbani ; Rosman, Diana ; Kaklamani, Virginia ; Baddi, Lisa ; Siddiqui, Farida S. ; Frankel, Wendy ; Prior, Thomas W. ; Schuller, David E. ; Agrawal, Amit ; Lang, Jas ; Dolan, M. Eileen ; Vokes, Everett E. ; Lane, William S. ; Huang, Chiang Ching ; Caldes, Trinidad ; Di Cristofano, Antonio ; Hampel, Heather ; Nilsson, IngMarie ; Von Heijne, Gunnar ; Fodde, Riccardo ; Murty, V. V V S ; De La Chapelle, Albert ; Weghorst, Christopher M. / Somatic acquisition and signaling of TGFBR1*6A in cancer. In: Journal of the American Medical Association. 2005 ; Vol. 294, No. 13. pp. 1634-1646.
@article{bb311e40b22946f2afd952c3d6de40a4,
title = "Somatic acquisition and signaling of TGFBR1*6A in cancer",
abstract = "Context: TGFBR1*6A is a common polymorphis of the type I transforming growth factor β receptor (TGFBR1). Epidemiological studies suggest that TGFBR1*6A may act as a tumor susceptibility allele. How TGFBR1*6A contributes to cancer development is largely unknown. Objectives: To determine whether TGFBR1*6A is somatically acquired by primary tumors and metastases during cancer development and whether the 3-amino acid deletion that differentiates TGFBR1*6A from TGFBR1 is part of the mature receptor or part of the signal sequence and to investigate TGFBR1*6A signaling in cancer cells. Design, Setting, and Patients: Tumor and germline tissues from 531 patients with a diagnosis of head and neck, colorectal, or breast cancer recruited from 3 centers in the United States and from 1 center in Spain from June 1, 1994, through June 30, 2004. In vitro translation assays, MCF-7 breast cancer cells stably transfected with TGFBR1*6A, TGFBR1, or the vector alone, DLD-1 colorectal cancer cells that endogenously carry TGFBR1*6A, and SW48 colorectal cancer cells that do not carry TGFBR1*6A. Main Outcome Measures: TGFBR1*6A somatic acquisition in cancer. Determination of the amino terminus of the mature TGFBR1*6A and TGFBR1 receptors. Determination of TGF-β-dependent cell proliferation. Results: TGFBR1*6A was somatically acquired in 13 of 44 (29.5{\%}) colorectal cancer metastases, in 4 of 157 (2.5{\%}) of colorectal tumors, in 4 of 226 (1.8{\%}) head and neck primary tumors, and in none of the 104 patients with breast cancer. TGFBR1*6A somatic acquisition is not associated with loss of heterozygosity, microsatellite instability, or a mutator phenotype. The signal sequences of TGFBR1 and TGFBR1*6A are cleaved at the same site resulting in identical mature receptors. TGFBR1*6A may switch TGF-β growth inhibitory signals into growth stimulatory signals in MCF-7 breast cancer cells and in DLD-1 colorectal cancer cells. Conclusions: TGFBR1*6A is somatically acquired in 29.5{\%} of liver metastases from colorectal cancer and may bestow cancer cells with a growth advantage in the presence of TGF-β. The functional consequences of this conversion appear to be mediated by the TGFBR1*6A signal sequence rather than by the mature receptor. The results highlight a new facet of TGF-β signaling in cancer and suggest that TGFBR1*6A may represent a potential therapeutic target in cancer.",
author = "Boris Pasche and Knobloch, {Thomas J.} and Yansong Bian and Junjian Liu and Sharbani Phukan and Diana Rosman and Virginia Kaklamani and Lisa Baddi and Siddiqui, {Farida S.} and Wendy Frankel and Prior, {Thomas W.} and Schuller, {David E.} and Amit Agrawal and Jas Lang and Dolan, {M. Eileen} and Vokes, {Everett E.} and Lane, {William S.} and Huang, {Chiang Ching} and Trinidad Caldes and {Di Cristofano}, Antonio and Heather Hampel and IngMarie Nilsson and {Von Heijne}, Gunnar and Riccardo Fodde and Murty, {V. V V S} and {De La Chapelle}, Albert and Weghorst, {Christopher M.}",
year = "2005",
month = "10",
day = "5",
doi = "10.1001/jama.294.13.1634",
language = "English (US)",
volume = "294",
pages = "1634--1646",
journal = "JAMA - Journal of the American Medical Association",
issn = "0002-9955",
publisher = "American Medical Association",
number = "13",

}

TY - JOUR

T1 - Somatic acquisition and signaling of TGFBR1*6A in cancer

AU - Pasche, Boris

AU - Knobloch, Thomas J.

AU - Bian, Yansong

AU - Liu, Junjian

AU - Phukan, Sharbani

AU - Rosman, Diana

AU - Kaklamani, Virginia

AU - Baddi, Lisa

AU - Siddiqui, Farida S.

AU - Frankel, Wendy

AU - Prior, Thomas W.

AU - Schuller, David E.

AU - Agrawal, Amit

AU - Lang, Jas

AU - Dolan, M. Eileen

AU - Vokes, Everett E.

AU - Lane, William S.

AU - Huang, Chiang Ching

AU - Caldes, Trinidad

AU - Di Cristofano, Antonio

AU - Hampel, Heather

AU - Nilsson, IngMarie

AU - Von Heijne, Gunnar

AU - Fodde, Riccardo

AU - Murty, V. V V S

AU - De La Chapelle, Albert

AU - Weghorst, Christopher M.

PY - 2005/10/5

Y1 - 2005/10/5

N2 - Context: TGFBR1*6A is a common polymorphis of the type I transforming growth factor β receptor (TGFBR1). Epidemiological studies suggest that TGFBR1*6A may act as a tumor susceptibility allele. How TGFBR1*6A contributes to cancer development is largely unknown. Objectives: To determine whether TGFBR1*6A is somatically acquired by primary tumors and metastases during cancer development and whether the 3-amino acid deletion that differentiates TGFBR1*6A from TGFBR1 is part of the mature receptor or part of the signal sequence and to investigate TGFBR1*6A signaling in cancer cells. Design, Setting, and Patients: Tumor and germline tissues from 531 patients with a diagnosis of head and neck, colorectal, or breast cancer recruited from 3 centers in the United States and from 1 center in Spain from June 1, 1994, through June 30, 2004. In vitro translation assays, MCF-7 breast cancer cells stably transfected with TGFBR1*6A, TGFBR1, or the vector alone, DLD-1 colorectal cancer cells that endogenously carry TGFBR1*6A, and SW48 colorectal cancer cells that do not carry TGFBR1*6A. Main Outcome Measures: TGFBR1*6A somatic acquisition in cancer. Determination of the amino terminus of the mature TGFBR1*6A and TGFBR1 receptors. Determination of TGF-β-dependent cell proliferation. Results: TGFBR1*6A was somatically acquired in 13 of 44 (29.5%) colorectal cancer metastases, in 4 of 157 (2.5%) of colorectal tumors, in 4 of 226 (1.8%) head and neck primary tumors, and in none of the 104 patients with breast cancer. TGFBR1*6A somatic acquisition is not associated with loss of heterozygosity, microsatellite instability, or a mutator phenotype. The signal sequences of TGFBR1 and TGFBR1*6A are cleaved at the same site resulting in identical mature receptors. TGFBR1*6A may switch TGF-β growth inhibitory signals into growth stimulatory signals in MCF-7 breast cancer cells and in DLD-1 colorectal cancer cells. Conclusions: TGFBR1*6A is somatically acquired in 29.5% of liver metastases from colorectal cancer and may bestow cancer cells with a growth advantage in the presence of TGF-β. The functional consequences of this conversion appear to be mediated by the TGFBR1*6A signal sequence rather than by the mature receptor. The results highlight a new facet of TGF-β signaling in cancer and suggest that TGFBR1*6A may represent a potential therapeutic target in cancer.

AB - Context: TGFBR1*6A is a common polymorphis of the type I transforming growth factor β receptor (TGFBR1). Epidemiological studies suggest that TGFBR1*6A may act as a tumor susceptibility allele. How TGFBR1*6A contributes to cancer development is largely unknown. Objectives: To determine whether TGFBR1*6A is somatically acquired by primary tumors and metastases during cancer development and whether the 3-amino acid deletion that differentiates TGFBR1*6A from TGFBR1 is part of the mature receptor or part of the signal sequence and to investigate TGFBR1*6A signaling in cancer cells. Design, Setting, and Patients: Tumor and germline tissues from 531 patients with a diagnosis of head and neck, colorectal, or breast cancer recruited from 3 centers in the United States and from 1 center in Spain from June 1, 1994, through June 30, 2004. In vitro translation assays, MCF-7 breast cancer cells stably transfected with TGFBR1*6A, TGFBR1, or the vector alone, DLD-1 colorectal cancer cells that endogenously carry TGFBR1*6A, and SW48 colorectal cancer cells that do not carry TGFBR1*6A. Main Outcome Measures: TGFBR1*6A somatic acquisition in cancer. Determination of the amino terminus of the mature TGFBR1*6A and TGFBR1 receptors. Determination of TGF-β-dependent cell proliferation. Results: TGFBR1*6A was somatically acquired in 13 of 44 (29.5%) colorectal cancer metastases, in 4 of 157 (2.5%) of colorectal tumors, in 4 of 226 (1.8%) head and neck primary tumors, and in none of the 104 patients with breast cancer. TGFBR1*6A somatic acquisition is not associated with loss of heterozygosity, microsatellite instability, or a mutator phenotype. The signal sequences of TGFBR1 and TGFBR1*6A are cleaved at the same site resulting in identical mature receptors. TGFBR1*6A may switch TGF-β growth inhibitory signals into growth stimulatory signals in MCF-7 breast cancer cells and in DLD-1 colorectal cancer cells. Conclusions: TGFBR1*6A is somatically acquired in 29.5% of liver metastases from colorectal cancer and may bestow cancer cells with a growth advantage in the presence of TGF-β. The functional consequences of this conversion appear to be mediated by the TGFBR1*6A signal sequence rather than by the mature receptor. The results highlight a new facet of TGF-β signaling in cancer and suggest that TGFBR1*6A may represent a potential therapeutic target in cancer.

UR - http://www.scopus.com/inward/record.url?scp=26044435160&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=26044435160&partnerID=8YFLogxK

U2 - 10.1001/jama.294.13.1634

DO - 10.1001/jama.294.13.1634

M3 - Article

C2 - 16204663

AN - SCOPUS:26044435160

VL - 294

SP - 1634

EP - 1646

JO - JAMA - Journal of the American Medical Association

JF - JAMA - Journal of the American Medical Association

SN - 0002-9955

IS - 13

ER -